LY3295668 Erbumine

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Metastatic Breast CancerNeuroblastomaSmall Cell Lung Cancer

Phase 1

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

CompletedNCT03898791

Eli Lilly and CompanySmall Cell Lung Cancer

Start: 2019-07-16End: 2021-03-30Updated: 2021-08-05

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

CompletedNCT03955939

Eli Lilly and CompanyMetastatic Breast Cancer

Start: 2019-08-02End: 2020-05-14Updated: 2020-06-01

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Active, not recruitingNCT04106219

Eli Lilly and CompanyNeuroblastoma

Start: 2020-06-11End: 2027-08-01Target: 71Updated: 2026-08-21

Related Papers

Preclinical Evaluation of JAB-2485, a Potent AURKA Inhibitor with High Selectivity and Favorable Pharmacokinetic Properties

ACS Omega2024-05-033 citations

A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.

Journal of Clinical Oncology2020-05-203 citations